# Expanded Access to Navitoclax

> **NCT03592576** · — · NO_LONGER_AVAILABLE · sponsor: **AbbVie**

## Conditions studied

- Myelofibrosis
- Acute Lymphocytic Leukemia (ALL)
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Navitoclax
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03592576
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03592576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03592576, "Expanded Access to Navitoclax". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03592576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*